Want to join the conversation?
$GILD's non-GAAP R&D expenses were $713MM in 3Q15, up 22% vs. last year due to the continued progression and expansion of its clinical studies, particularly its HIV based program. Further SG&A expenses were down 4% YoverY to $850MM, primarily due to a cumulative catch-up of the branded prescription drug fee recorded in the same period in 2014.
$CRM on the pop today.. big bubble.
Slumping and down the drain... $HDSN. Flush out your holdings !
$KITE I am loving this one... really flying like a kite today :-)